Surprisingly, AR+ cancer cell lines reduce their proliferation in response to either AR agonists or AR antagonists, in the latter case even AR- lines (BT-20, MDA-MB-468, SUM-159PT) are susceptible to enzalutamide and bicalutamide (this can be explained by the drugs’ affinity towards GABA-A, CYP27A1 and PR). The gene discussed is AR; the disease is cancer.